Update us on the transgender controversies.
Distinguish psychological/emotional, androgynous.
What is the situation re trans surgeries and hormones for minors?
This is a large and genuinely complex topic, so let me try to give you a structured, honest overview, distinguishing the genuinely contested empirical questions from the political ones.
I. The Political and Legal Landscape (US, 2025–26)
The pace of legislation is extraordinary. In 2026, around 740 bills are under consideration across the country that would negatively impact trans and gender non-conforming people, and 2025 was the sixth consecutive record-breaking year for total bills considered.
At the federal level, the Trump administration's approach has been sweeping. In January 2025, a list of "forbidden terms" was reportedly distributed within government health agencies, instructing employees to avoid words like "gender," "transgender," or "LGBT." Scientific grants were revoked or reviewed on the basis that LGBT topics had been mentioned in the research.
In August 2025 the administration threatened to pull federal funding from sex education programs that mention transgender people.
A final rule from June 2025 prohibits gender-affirming care from being covered as an Essential Health Benefit in ACA plans beginning in plan year 2026.
At the state level, by the end of December 2025, 29 states had adopted at least one restrictive law, while many states enacted "shield" laws protecting gender-affirming care providers and families from consequences originating in states where such care has been restricted.
II. The Psychological and Emotional Controversies
These are genuinely contested empirical and conceptual questions, not merely political ones, and they deserve careful treatment.
A. Desistance
One of the sharpest debates concerns whether gender dysphoria in children is stable or tends to resolve. Older follow-up studies found desistance rates of 65–94%, meaning a large majority of children who presented with gender dysphoria eventually ceased to identify as transgender. More recent clinical literature still cites desistance rates of 75–95% in children with gender dysphoria when "watchful waiting" is offered, though early evidence suggests this rate decreases if children are socially and medically affirmed early.
The counter-argument, made by many gender-affirmative clinicians, is that the older desistance studies used broader diagnostic criteria and likely included many children who were simply gender-nonconforming or proto-gay, not truly trans. Critics of the desistance literature argue that because diagnostic criteria for gender dysphoria were less stringent in the past, those earlier studies included many children who today would not be diagnosed with gender dysphoria at all — gay boys, for instance, who were brought to clinics because they didn't fit gender norms.
The methodological dispute here is real and unresolved.
B. Rapid-Onset Gender Dysphoria (ROGD)
ROGD was first introduced by Lisa Littman in a 2018 study of parental reports. It describes a subset of youth — primarily natal females — with no childhood indicators of gender dysphoria but with a sudden emergence of symptoms during or after puberty, with the hypothesis that identifying as transgender may serve as a maladaptive coping mechanism for underlying mental health issues, linked to social influences from peer groups and social media.
This remains highly contested. Critics note that the original study relied on parental reports from websites hostile to transition, not on clinical populations or the adolescents themselves. Supporters argue that the dramatic demographic shift in referrals — from predominantly natal males to predominantly natal females — demands explanation, and that ROGD offers a plausible one.
C. Comorbidities and Androgynous vs. Dysphoric Presentations
This is crucial to distinguish. The clinical picture has become significantly more complex because the population presenting to gender clinics has changed. Alongside classic gender dysphoria (a deep, persistent, often childhood-onset identification with the other sex, frequently associated with same-sex attraction), there is now a much larger group of adolescents, particularly natal females, presenting with gender distress alongside significant rates of autism, depression, anxiety, trauma histories, and self-harm.
Critics note that children presenting at gender clinics were, in many cases, psychologically complex with comorbidities, and some were recommended for medicalized treatment after as few as four assessment meetings, during which very little psychological work could have occurred. Wiley Online Library
The distinction your question flags — between a classically dysphoric child whose cross-sex identification is longstanding and ego-syntonic, versus an adolescent whose gender distress may be more intertwined with trauma, social contagion, or an androgynous/non-binary sense of self that doesn't require medicalization — is exactly where clinicians now most sharply disagree. Some see these as categorically distinct populations requiring different treatment approaches; others argue the distinction is being weaponized to deny care to legitimate patients.
D. Detransition
One study of 78 young adults who had previously identified as transgender found that the most common reason given for initial trans-identification was confusing mental health issues or reactions to trauma for gender dysphoria, and that participants reported dramatic improvements in psychological health since detransition, including marked decreases in self-harm and gender dysphoria.
Over 90% of this detransition sample were natal females, and 53% believed that rapid-onset gender dysphoria applied to their experience.
This kind of study is contested, not least for its sampling methods (self-selected populations from detransitioner communities), but it has shaped policy discussions considerably.
III. Trans Medical Care for Minors: Hormones and Surgery
This is where the international picture has shifted most dramatically.
The Cass Review (UK, 2024)
The pivotal document is the Cass Review, commissioned by NHS England, published April 2024. The Cass Review constitutes the most comprehensive evaluation of pediatric transgender healthcare to date and concluded that clinical practice had outstripped the evidence base — that clinicians were providing irreversible treatments amid significant risks involving fertility, sexual function, bone mineralization, and cognition, despite a lack of evidence regarding effectiveness for reduction in gender dysphoria and for long-term mental health benefits.
It recommended puberty blockers only within a clinical research framework and "extreme caution" with cross-sex hormones in 16–17-year-olds.
Following publication, NHS England did not issue any new prescriptions of gender-affirming hormones to minors in the year after the report, even though they were not formally banned, with the NHS instead prioritising "holistic care."
International ripple effects
In May 2025, a Trump administration HHS report expressed strong support for the Cass Review, calling it the "most comprehensive" and "most influential" evaluation of youth gender-affirming care to date — though critics noted it was co-authored by a founder of an anti-trans nonprofit.
In February 2026, the American Society of Plastic Surgeons became the first major US medical association to change its guidance on gender-affirming surgery for minors, recommending that chest, genital, and facial surgeries not be performed until age 19.
The state of the evidence debate
Both sides of this debate include serious researchers. The dispute is genuinely about evidentiary standards, not simply politics. Critics of gender-affirming care for minors argue that the evidence is of very low quality — that observational studies claiming benefits are confounded, under-powered, or lacking long-term follow-up. Defenders argue that randomized controlled trials are unethical in this population, that decades of clinical experience with the Dutch protocol support the approach, and that restricting care causes documented harm through untreated dysphoria, depression, and suicidality.
Even critics and defenders largely agree on one point: that gender-affirming medical interventions are not appropriate for all transgender adolescents, and that individual assessment is required — the debate is about what the threshold and safeguards should be, not whether medicalization is always warranted.
It is also worth noting that despite the perception of widespread medicalization, an analysis of US insurance claims found that only 2–4% of youth diagnosed with gender dysphoria receive puberty-pausing medications or gender-affirming hormones — most transgender youth do not receive medical treatments.
Summary
The trans controversy is not a single debate but a cluster of overlapping ones: a genuine scientific dispute about evidence quality and clinical standards; a harder philosophical/ethical question about who can consent to what at what age and under what conditions; a psychologically subtle question about distinguishing classical dysphoria from androgynous or gender-nonconforming presentations that may not require medicalization; and a brutal political fight in which these genuine uncertainties are being exploited for culture-war purposes well beyond what the evidence warrants in either direction.
You missed discussion of persons born with sex organ anomalies or with an extra chromosome from the other sex
You're right to flag this — it's a genuinely distinct biological category that often gets conflated with, or absorbed into, the transgender debate in ways that muddy rather than clarify things.
Intersex Conditions (Differences of Sex Development, DSD)
The clinical term is Differences of Sex Development (DSD), though many affected individuals prefer "intersex." This covers a heterogeneous group of conditions, not a single phenomenon.
The major categories include:
Chromosomal variations
The clearest cases of your "extra chromosome from the other sex" point. Klinefelter syndrome (XXY) affects roughly 1 in 600 males — producing a male phenotype with reduced testosterone, often infertility, sometimes gynecomastia, but typically a stable male gender identity. XXY is therefore not a "trans" condition in any meaningful sense; most Klinefelter men are straightforwardly male and never question their gender. Similarly, XYY syndrome (Jacob's syndrome) produces phenotypically typical males.
On the female side, Turner syndrome (45,X) involves absence of a second sex chromosome. These conditions raise medical questions (fertility, hormonal supplementation, cardiac monitoring in Turner's) but are categorically different from gender dysphoria.
Congenital Adrenal Hyperplasia (CAH). The most common DSD. In 46,XX females, excessive adrenal androgens cause varying degrees of virilization of the genitalia in utero. Most CAH women have a female gender identity and are unambiguously female — their situation is a medical one involving cortisol deficiency and genital surgery decisions, not a trans one. However, studies do find elevated rates of gender dysphoria and bisexuality in CAH women, which is significant for understanding the prenatal hormonal basis of gender identity.
Androgen Insensitivity Syndrome (AIS). 46,XY individuals whose cells cannot respond to androgens. Complete AIS (CAIS) produces individuals who are phenotypically female in all external respects, typically raised as girls, and who almost universally have a female gender identity — despite having XY chromosomes and undescended testes. This is the clearest refutation of the simplistic "chromosomes = sex = gender" position. Partial AIS produces intermediate presentations.
5-alpha reductase deficiency and 17-beta HSD deficiency. Conditions in which 46,XY individuals are born with female-appearing or ambiguous genitalia, often raised as girls, but then virilize substantially at puberty due to a surge in testosterone. In the communities in the Dominican Republic and Papua New Guinea where this is relatively common (the guevedoces — "eggs at twelve"), the majority switch to living as men at puberty and maintain a male identity thereafter. This is one of the most compelling bodies of evidence for biological influences on gender identity.
The Historical Controversy: John Money and Surgical Assignment
The history here is important and deeply troubling. From roughly the 1950s through the 1990s, the dominant clinical approach — associated especially with John Money at Johns Hopkins — was to surgically assign infants with ambiguous genitalia to whichever sex was easiest to construct surgically (often female, since constructing a vagina was deemed technically simpler than constructing a functional penis). The assumption was that gender identity was primarily a product of socialization and could be shaped by surgical and hormonal treatment.
The catastrophic failure of this approach was demonstrated most vividly by the David Reimer case — a biologically normal male whose penis was destroyed in a circumcision accident, who was then raised as a girl under Money's guidance, was reported (falsely, it emerged) as a success, but who actually suffered severe psychological distress, eventually lived as a male, and died by suicide in 2004. The case is exhaustively documented by Milton Diamond and Keith Sigmundsson, and later by John Colapinto.
The legacy is that non-consensual "normalizing" genital surgery on intersex infants is now widely condemned by intersex advocacy organizations and increasingly by medical bodies. The harm is both physical (loss of sensation, scarring, repeated surgical interventions) and psychological (the deception often involved, the removal of choice from the person most affected).
The Conflation Problem
The politically important point is this: intersex conditions do not straightforwardly support either side of the trans debate, though both sides recruit them.
Those who argue for the biological basis of gender identity point to AIS (a person with XY chromosomes living contentedly as female) and 5-alpha reductase deficiency (socialized female, living as male post-puberty) as evidence that gender identity has deep biological roots independent of socialization. This is fair.
But intersex conditions are not the same as gender dysphoria in chromosomally typical individuals. The transgender population consists overwhelmingly of people who are 46,XX or 46,XY with typical sexual differentiation — their sex is not ambiguous biologically, even if their gender identity doesn't align with it. To use intersex biology as direct evidence about the trans condition requires inferential steps that aren't always made carefully.
The cruder political move — claiming that intersex existence proves biological sex is "not binary" or "a spectrum" — is also sloppy. The existence of rare chromosomal and developmental anomalies in a system doesn't make the underlying binary dimorphic structure of human reproduction a myth; it means the system is imperfect in its execution, as biological systems generally are.
Current Controversies in Intersex Care
The live debates concern: whether any surgical intervention on genitalia should be deferred until the child can consent; how to handle infants with severe virilization or ambiguity; and how to ensure that individuals with DSDs are not subsumed under the politically charged trans framework when their conditions and interests are distinct. Many intersex advocates are in fact frustrated by the conflation with trans issues, since it obscures the specific harms they face — particularly the history of non-consensual surgery and medical deception — in favor of a broader gender politics that doesn't necessarily speak to their experience.
Distinguish psychological/emotional, androgynous.
What is the situation re trans surgeries and hormones for minors?
This is a large and genuinely complex topic, so let me try to give you a structured, honest overview, distinguishing the genuinely contested empirical questions from the political ones.
I. The Political and Legal Landscape (US, 2025–26)
The pace of legislation is extraordinary. In 2026, around 740 bills are under consideration across the country that would negatively impact trans and gender non-conforming people, and 2025 was the sixth consecutive record-breaking year for total bills considered.
At the federal level, the Trump administration's approach has been sweeping. In January 2025, a list of "forbidden terms" was reportedly distributed within government health agencies, instructing employees to avoid words like "gender," "transgender," or "LGBT." Scientific grants were revoked or reviewed on the basis that LGBT topics had been mentioned in the research.
In August 2025 the administration threatened to pull federal funding from sex education programs that mention transgender people.
A final rule from June 2025 prohibits gender-affirming care from being covered as an Essential Health Benefit in ACA plans beginning in plan year 2026.
At the state level, by the end of December 2025, 29 states had adopted at least one restrictive law, while many states enacted "shield" laws protecting gender-affirming care providers and families from consequences originating in states where such care has been restricted.
II. The Psychological and Emotional Controversies
These are genuinely contested empirical and conceptual questions, not merely political ones, and they deserve careful treatment.
A. Desistance
One of the sharpest debates concerns whether gender dysphoria in children is stable or tends to resolve. Older follow-up studies found desistance rates of 65–94%, meaning a large majority of children who presented with gender dysphoria eventually ceased to identify as transgender. More recent clinical literature still cites desistance rates of 75–95% in children with gender dysphoria when "watchful waiting" is offered, though early evidence suggests this rate decreases if children are socially and medically affirmed early.
The counter-argument, made by many gender-affirmative clinicians, is that the older desistance studies used broader diagnostic criteria and likely included many children who were simply gender-nonconforming or proto-gay, not truly trans. Critics of the desistance literature argue that because diagnostic criteria for gender dysphoria were less stringent in the past, those earlier studies included many children who today would not be diagnosed with gender dysphoria at all — gay boys, for instance, who were brought to clinics because they didn't fit gender norms.
The methodological dispute here is real and unresolved.
B. Rapid-Onset Gender Dysphoria (ROGD)
ROGD was first introduced by Lisa Littman in a 2018 study of parental reports. It describes a subset of youth — primarily natal females — with no childhood indicators of gender dysphoria but with a sudden emergence of symptoms during or after puberty, with the hypothesis that identifying as transgender may serve as a maladaptive coping mechanism for underlying mental health issues, linked to social influences from peer groups and social media.
This remains highly contested. Critics note that the original study relied on parental reports from websites hostile to transition, not on clinical populations or the adolescents themselves. Supporters argue that the dramatic demographic shift in referrals — from predominantly natal males to predominantly natal females — demands explanation, and that ROGD offers a plausible one.
C. Comorbidities and Androgynous vs. Dysphoric Presentations
This is crucial to distinguish. The clinical picture has become significantly more complex because the population presenting to gender clinics has changed. Alongside classic gender dysphoria (a deep, persistent, often childhood-onset identification with the other sex, frequently associated with same-sex attraction), there is now a much larger group of adolescents, particularly natal females, presenting with gender distress alongside significant rates of autism, depression, anxiety, trauma histories, and self-harm.
Critics note that children presenting at gender clinics were, in many cases, psychologically complex with comorbidities, and some were recommended for medicalized treatment after as few as four assessment meetings, during which very little psychological work could have occurred. Wiley Online Library
The distinction your question flags — between a classically dysphoric child whose cross-sex identification is longstanding and ego-syntonic, versus an adolescent whose gender distress may be more intertwined with trauma, social contagion, or an androgynous/non-binary sense of self that doesn't require medicalization — is exactly where clinicians now most sharply disagree. Some see these as categorically distinct populations requiring different treatment approaches; others argue the distinction is being weaponized to deny care to legitimate patients.
D. Detransition
One study of 78 young adults who had previously identified as transgender found that the most common reason given for initial trans-identification was confusing mental health issues or reactions to trauma for gender dysphoria, and that participants reported dramatic improvements in psychological health since detransition, including marked decreases in self-harm and gender dysphoria.
Over 90% of this detransition sample were natal females, and 53% believed that rapid-onset gender dysphoria applied to their experience.
This kind of study is contested, not least for its sampling methods (self-selected populations from detransitioner communities), but it has shaped policy discussions considerably.
III. Trans Medical Care for Minors: Hormones and Surgery
This is where the international picture has shifted most dramatically.
The Cass Review (UK, 2024)
The pivotal document is the Cass Review, commissioned by NHS England, published April 2024. The Cass Review constitutes the most comprehensive evaluation of pediatric transgender healthcare to date and concluded that clinical practice had outstripped the evidence base — that clinicians were providing irreversible treatments amid significant risks involving fertility, sexual function, bone mineralization, and cognition, despite a lack of evidence regarding effectiveness for reduction in gender dysphoria and for long-term mental health benefits.
It recommended puberty blockers only within a clinical research framework and "extreme caution" with cross-sex hormones in 16–17-year-olds.
Following publication, NHS England did not issue any new prescriptions of gender-affirming hormones to minors in the year after the report, even though they were not formally banned, with the NHS instead prioritising "holistic care."
International ripple effects
In May 2025, a Trump administration HHS report expressed strong support for the Cass Review, calling it the "most comprehensive" and "most influential" evaluation of youth gender-affirming care to date — though critics noted it was co-authored by a founder of an anti-trans nonprofit.
In February 2026, the American Society of Plastic Surgeons became the first major US medical association to change its guidance on gender-affirming surgery for minors, recommending that chest, genital, and facial surgeries not be performed until age 19.
The state of the evidence debate
Both sides of this debate include serious researchers. The dispute is genuinely about evidentiary standards, not simply politics. Critics of gender-affirming care for minors argue that the evidence is of very low quality — that observational studies claiming benefits are confounded, under-powered, or lacking long-term follow-up. Defenders argue that randomized controlled trials are unethical in this population, that decades of clinical experience with the Dutch protocol support the approach, and that restricting care causes documented harm through untreated dysphoria, depression, and suicidality.
Even critics and defenders largely agree on one point: that gender-affirming medical interventions are not appropriate for all transgender adolescents, and that individual assessment is required — the debate is about what the threshold and safeguards should be, not whether medicalization is always warranted.
It is also worth noting that despite the perception of widespread medicalization, an analysis of US insurance claims found that only 2–4% of youth diagnosed with gender dysphoria receive puberty-pausing medications or gender-affirming hormones — most transgender youth do not receive medical treatments.
Summary
The trans controversy is not a single debate but a cluster of overlapping ones: a genuine scientific dispute about evidence quality and clinical standards; a harder philosophical/ethical question about who can consent to what at what age and under what conditions; a psychologically subtle question about distinguishing classical dysphoria from androgynous or gender-nonconforming presentations that may not require medicalization; and a brutal political fight in which these genuine uncertainties are being exploited for culture-war purposes well beyond what the evidence warrants in either direction.
You missed discussion of persons born with sex organ anomalies or with an extra chromosome from the other sex
You're right to flag this — it's a genuinely distinct biological category that often gets conflated with, or absorbed into, the transgender debate in ways that muddy rather than clarify things.
Intersex Conditions (Differences of Sex Development, DSD)
The clinical term is Differences of Sex Development (DSD), though many affected individuals prefer "intersex." This covers a heterogeneous group of conditions, not a single phenomenon.
The major categories include:
Chromosomal variations
The clearest cases of your "extra chromosome from the other sex" point. Klinefelter syndrome (XXY) affects roughly 1 in 600 males — producing a male phenotype with reduced testosterone, often infertility, sometimes gynecomastia, but typically a stable male gender identity. XXY is therefore not a "trans" condition in any meaningful sense; most Klinefelter men are straightforwardly male and never question their gender. Similarly, XYY syndrome (Jacob's syndrome) produces phenotypically typical males.
On the female side, Turner syndrome (45,X) involves absence of a second sex chromosome. These conditions raise medical questions (fertility, hormonal supplementation, cardiac monitoring in Turner's) but are categorically different from gender dysphoria.
Congenital Adrenal Hyperplasia (CAH). The most common DSD. In 46,XX females, excessive adrenal androgens cause varying degrees of virilization of the genitalia in utero. Most CAH women have a female gender identity and are unambiguously female — their situation is a medical one involving cortisol deficiency and genital surgery decisions, not a trans one. However, studies do find elevated rates of gender dysphoria and bisexuality in CAH women, which is significant for understanding the prenatal hormonal basis of gender identity.
Androgen Insensitivity Syndrome (AIS). 46,XY individuals whose cells cannot respond to androgens. Complete AIS (CAIS) produces individuals who are phenotypically female in all external respects, typically raised as girls, and who almost universally have a female gender identity — despite having XY chromosomes and undescended testes. This is the clearest refutation of the simplistic "chromosomes = sex = gender" position. Partial AIS produces intermediate presentations.
5-alpha reductase deficiency and 17-beta HSD deficiency. Conditions in which 46,XY individuals are born with female-appearing or ambiguous genitalia, often raised as girls, but then virilize substantially at puberty due to a surge in testosterone. In the communities in the Dominican Republic and Papua New Guinea where this is relatively common (the guevedoces — "eggs at twelve"), the majority switch to living as men at puberty and maintain a male identity thereafter. This is one of the most compelling bodies of evidence for biological influences on gender identity.
The Historical Controversy: John Money and Surgical Assignment
The history here is important and deeply troubling. From roughly the 1950s through the 1990s, the dominant clinical approach — associated especially with John Money at Johns Hopkins — was to surgically assign infants with ambiguous genitalia to whichever sex was easiest to construct surgically (often female, since constructing a vagina was deemed technically simpler than constructing a functional penis). The assumption was that gender identity was primarily a product of socialization and could be shaped by surgical and hormonal treatment.
The catastrophic failure of this approach was demonstrated most vividly by the David Reimer case — a biologically normal male whose penis was destroyed in a circumcision accident, who was then raised as a girl under Money's guidance, was reported (falsely, it emerged) as a success, but who actually suffered severe psychological distress, eventually lived as a male, and died by suicide in 2004. The case is exhaustively documented by Milton Diamond and Keith Sigmundsson, and later by John Colapinto.
The legacy is that non-consensual "normalizing" genital surgery on intersex infants is now widely condemned by intersex advocacy organizations and increasingly by medical bodies. The harm is both physical (loss of sensation, scarring, repeated surgical interventions) and psychological (the deception often involved, the removal of choice from the person most affected).
The Conflation Problem
The politically important point is this: intersex conditions do not straightforwardly support either side of the trans debate, though both sides recruit them.
Those who argue for the biological basis of gender identity point to AIS (a person with XY chromosomes living contentedly as female) and 5-alpha reductase deficiency (socialized female, living as male post-puberty) as evidence that gender identity has deep biological roots independent of socialization. This is fair.
But intersex conditions are not the same as gender dysphoria in chromosomally typical individuals. The transgender population consists overwhelmingly of people who are 46,XX or 46,XY with typical sexual differentiation — their sex is not ambiguous biologically, even if their gender identity doesn't align with it. To use intersex biology as direct evidence about the trans condition requires inferential steps that aren't always made carefully.
The cruder political move — claiming that intersex existence proves biological sex is "not binary" or "a spectrum" — is also sloppy. The existence of rare chromosomal and developmental anomalies in a system doesn't make the underlying binary dimorphic structure of human reproduction a myth; it means the system is imperfect in its execution, as biological systems generally are.
Current Controversies in Intersex Care
The live debates concern: whether any surgical intervention on genitalia should be deferred until the child can consent; how to handle infants with severe virilization or ambiguity; and how to ensure that individuals with DSDs are not subsumed under the politically charged trans framework when their conditions and interests are distinct. Many intersex advocates are in fact frustrated by the conflation with trans issues, since it obscures the specific harms they face — particularly the history of non-consensual surgery and medical deception — in favor of a broader gender politics that doesn't necessarily speak to their experience.
Go to the NEXT CHAPTER.
Reach the Table of Content & Link List HERE
No comments:
Post a Comment